NAMPT Antibody

Code CSB-PA015422ESR2HU
Size US$166
Order now
Image
  • Western blot
    All lanes: Nicotinamide phosphoribosyltransferase antibody at 4μg/ml
    Lane 1: Mouse heart tissue
    Lane 2: Mouse liver tissue
    Lane 3: Mouse skeletal muscle tissue
    Secondary
    Goat polyclonal to rabbit IgG at 1/10000 dilution
    Predicted band size: 56 kDa
    Observed band size: 56 kDa

  • Immunohistochemistry of paraffin-embedded human liver tissue using CSB-PA015422ESR2HU at dilution of 1:100

  • Immunohistochemistry of paraffin-embedded human kidney tissue using CSB-PA015422ESR2HU at dilution of 1:100

Have Questions? Leave a Message or Start an on-line Chat

Product Details

Full Product Name
Rabbit anti-Homo sapiens (Human) NAMPT Polyclonal antibody
Uniprot No.
Target Names
NAMPT
Alternative Names
1110035O14Rik antibody; AI314458 antibody; AI480535 antibody; DKFZP666B131 antibody; EC 2.4.2.12 antibody; MGC117256 antibody; NAmPRTase antibody; Nampt antibody; NAMPT_HUMAN antibody; Nicotinamide phosphoribosyltransferase antibody; PBEF 1 antibody; PBEF antibody; PBEF1 antibody; Pre B cell colony enhancing factor 1 antibody; Pre B cell colony enhancing factor antibody; Pre B cell enhancing factor antibody; Pre-B cell-enhancing factor antibody; Pre-B-cell colony-enhancing factor 1 antibody; VF antibody; Visfatin antibody
Raised in
Rabbit
Species Reactivity
Human, Mouse
Immunogen
Recombinant Human Nicotinamide phosphoribosyltransferase protein (1-280AA)
Immunogen Species
Homo sapiens (Human)
Conjugate
Non-conjugated
Clonality
Polyclonal
Isotype
IgG
Purification Method
Antigen Affinity Purified
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
PBS with 0.02% sodium azide, 50% glycerol, pH7.3.
Form
Liquid
Tested Applications
ELISA, WB, IHC
Recommended Dilution
Application Recommended Dilution
WB 1:500-1:5000
IHC 1:20-1:200
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Catalyzes the condensation of nicotinamide with 5-phosphoribosyl-1-pyrophosphate to yield nicotinamide mononucleotide, an intermediate in the biosynthesis of NAD. It is the rate limiting component in the mammalian NAD biosynthesis pathway. The secreted form behaves both as a cytokine with immunomodulating properties and an adipokine with anti-diabetic properties, it has no enzymatic activity, partly because of lack of activation by ATP, which has a low level in extracellular space and plasma. Plays a role in the modulation of circadian clock function. NAMPT-dependent oscillatory production of NAD regulates oscillation of clock target gene expression by releasing the core clock component: CLOCK-ARNTL/BMAL1 heterodimer from NAD-dependent SIRT1-mediated suppression.
Gene References into Functions
  1. chemerin and leptin are elevated and omentin-1 and visfatin levels are decreased in Gestational diabetes mellitus women complicated by obesity. PMID: 29337272
  2. fat mass percentage together with HOMA-IR are the most significant predictors of visfatin/NAMPT serum elevation in hyperthyroid patients. PMID: 30184561
  3. Serum levels of visfatin were significant higher in HCC patients than healthy subjects. It was significantly associated with the histology and metastasis. Visfatin induced miR-21 expression and cell migration in HepG2 cells. PMID: 29808800
  4. Knockdown of Nampt expression increased the expression of Aggrecan and Collagen II inhibited by IL-1beta and the autophagic markers, LC3 and Beclin-1, confirmed APO866 induced NP cell autophagy and blocks IL-1beta induction considerably. PMID: 30261504
  5. The study showed for the first time serum omentin and visfatin levels to be decreased after lung transplantation in end-stage lung disease patients PMID: 29277835
  6. We conclude that the low placental visfatin (NAMPT) expression and poor metabolic control in the 3(rd) trimester of pregnancy may have a role in stimulating fetal overgrowth in T1DM pregnancy. PMID: 29769421
  7. no significant differences in genotype frequencies between preterm birth cases and controls; but maternal blood level higher in A allele carriers of rs61330082 PMID: 28482725
  8. higher visfatin levels in erosive hand osteoarthritis (HOA) in comparison to nnonerosive HOA PMID: 29105498
  9. obese subjects with GG genotype of visfatin who had high PUFA-intake diets had lower hip z scores and T scores, unlike the other genotypes PMID: 29355093
  10. Review/Meta-analysis: circulating visfatin levels were significantly higher in patients with rheumatoid arthritis and a positive correlation was suggested with disease activity. PMID: 28205390
  11. Observed NAMPT overexpression in patients with Graves' disease with and without (GO) orbitopathy and its relatively low levels in thyroids of patients with Graves' disease (GD)without eye changes do not confirm causal relationship between NAMPT level and orbitopathy, but this needs further investigation. PMID: 29546048
  12. Visfatin seems to be a good marker of endometrial cancer progress. High visfatin serum level predicts poor prognosis in endometrial cancer patients. PMID: 29516012
  13. NAMPT expression downregulation by mir-206 reduces cell survival of breast cancer cells PMID: 29886033
  14. No correlation between IDH1/2 mutation status and sensitivity for NAMPT inhibitors was observed. Strikingly, higher methylation of the NAPRT promoter was observed in high-grade versus low-grade chondrosarcomas. In conclusion, this study identified NAMPT as a potential target for treatment of chondrosarcoma PMID: 28860121
  15. NAMPT as a key player in BRAFi resistance and melanoma cell plasticity PMID: 29567766
  16. This study has shown Resistin, and Visfatin synergistically increased gastric cancer cell proliferation and enhanced the telomerase gene expression, showing that these two hormones in gastric cancer tissue could cooperatively accelerate cancer cell growth PMID: 29228527
  17. Serum Nampt was increased in diabetic nephropathy patients. PMID: 28699485
  18. NAMPT is highly upregulated in human gingival fibroblasts, while its enzymatic activity acts as a crucial mediator of periodontal inflammation and alveolar bone destruction via regulation of catabolic factors COX-2, MMP1, and MMP3 levels. PMID: 28819322
  19. Results show that adiponectin, resistin and visfatin are present in osteophytes but have no direct influence on osteophyte development. Although these adipokines induce several inflammatory mediators, they do not affect osteoblast- or chondrocyte-related mechanisms of osteophyte development. PMID: 27884778
  20. Cells were treated with 10 nM FK866, an NAMPT inhibitor, resulting in a decrease in the cellular NAD level. PMID: 28714034
  21. data indicate that visfatin induces endothelial progenitor cells apoptosis by increasing the expression of pro-inflammatory mediators partly through the regulation of NF-kappaB. PMID: 28677720
  22. study thus demonstrates that the inhibition of PBEF attenuates oxidative stress and inflammation induced by hyperoxia in EA.hy926 cells. PMID: 28677752
  23. hsa_circ_0005105 can promote extracellular matrix (ECM) degradation by regulating the expression of miR-26a target NAMPT. PMID: 28276108
  24. Careful characterization of the kinetics of NAMPT inhibition in vivo allowed us to optimize dosing to produce sufficient NAD(+) depletion over time that resulted in efficacy in an HCT116 xenograft model. Our data demonstrate that direct phosphoribosylation of competitive inhibitors by the NAMPT enzyme is not required for potent in vitro cellular activity or in vivo antitumor efficacy. PMID: 28468779
  25. Results suggested that visfatin -1535C>T polymorphisms might be associated with decreased risk of HBV-HCC among the ethnic Zhuang population in Guangxi, China. PMID: 27792999
  26. the present study elucidated the pathophysiological role of visfatin in breast cancer and revealed a proliferative and protective role for visfatin PMID: 28442350
  27. serum level associated with increased odds of severe hypertension PMID: 26869250
  28. In this cohort of resistant hypertension patients diagnosed with ambulatory blood pressure measurements, the investigators found an independent correlation between higher visfatin levels and the presence of resistant hypertension and left ventricular hypertrophy. PMID: 28240682
  29. A potential oncogenic role of Nampt in Waldenstrom macroglobulinemia cells. PMID: 27287071
  30. factor with strong correlation with high visfatin values (p=0.001). High Visfatin levels seem to be strongly correlated with the presence and severity of peripheral arterial occlusive disease. PMID: 28073026
  31. These results suggested that the plasma visfatin level is associated with the presence of hepatocellular carcinoma (HCC), and that a higher plasma visfatin level may be important in the pathogenesis of HCC. PMID: 27770715
  32. Increased expression of visfatin are associated with a more aggressive phenotype of colorectal carcinoma patients. It can trigger the epithelial mesenchymal transformation of CRC cells via Akt/GSK-3beta/beta-catenin signals. PMID: 27058759
  33. Results showed that rs34861192 of RETN and rs13237989 of NAMPT synergistically affected the levels of insulin and glycemic index. PMID: 29101068
  34. In summary, NAMPT is produced in human spermatozoa in a maturation-dependent manner. PMID: 27566659
  35. Non-surgical periodontal treatment resulted in a significant reduction in gingival crevicular fluid and serum visfatin levels. Furthermore, visfatin levels increased with inflammation and decreased following periodontal treatment. Our findings suggest that visfatin is an inflammatory biomarker of periodontal disease PMID: 28025432
  36. Accordingly, our results demonstrated that NAMPT is a prognostic marker in melanoma, and the identificationofNAMPT-E2F2-SIRT1 pathway establishes another link between NAMPT and apoptosis events in melanoma, with therapeutic implications for this deadly cancer. PMID: 28919418
  37. systemic circulating NAMPT levels were closely associated with NAMPT release from corresponding cultured PBMCs. In conclusion, NAMPT is selectively increased in states of acute but not chronic inflammation in children PMID: 28837586
  38. It focusing on NAMPT immunometabolic function as a metabokine, NAMPT secretion, NAMPT mechanism of action and possible roles in the cancer micro-environment. PMID: 27128025
  39. Authors show the gene encoding nicotinic acid phosphoribosyltransferase (NAPRT), a second NAD(+)-producing enzyme, is amplified and overexpressed in a subset of common types of cancer, including ovarian cancer. PMID: 28507103
  40. This study shows that expression of SDF-1alpha, eNOS and VEGF were significantly higher in uterine leiomyoma than myometrium with a different expression pattern according to the size of uterine leiomyoma. However, expressions of visfatin and leptin had no significant differences between the two groups. PMID: 28010141
  41. Results indicate that increased serum visfatin levels are associated with poor prognosis of hepatocellular carcinoma (HCC), and visfatin may be a potential therapeutic target of HCC. PMID: 28178643
  42. Nampt expression is a reliable marker of progression in cervical dysplasia and squamous cell carcinoma. PMID: 28870901
  43. Visfatin increases the nuclear translocation of Akt and its binding with ABCC1. These data showed that visfatin can decrease doxorubicin sensitivity of Non-small-cell lung cancer cells via activation of Akt/MRP1. PMID: 28762597
  44. Results suggest a mechanism by which tumor cells protect themselves against glucose deprivation-induced oxidative stress by utilizing nicotinamide phosphoribosyltransferase (NAMPT) to maintain NADPH levels. PMID: 26568303
  45. The combination of upregulation of the NAD(+) de novo synthesis pathway through QPRT over-expression and NAMPT mutation confers resistance to GMX1778, but the cells are only partially resistant to next-generation NAMPT inhibitors. The resistance mechanisms uncovered herein provide a potential avenue to continue exploration of next generation NAMPT inhibitors to treat neoplasms in the clinic. PMID: 28756225
  46. this study shows that upstream visfatin SNPs could potentially affect phenotypic outcome in obese children through alteration of circulating visfatin level. PMID: 27887573
  47. Lack of changes in serum visfatin level despite the changes in visfatin mRNA expression of adipose tissue suggests paracrine effect of visfatin rather than endocrine PMID: 26486101
  48. Ascending aorta from aortic aneurysm patient,s revealed an inverse relationship between smooth muscle cell NAMPT content and aortic diameter. PMID: 28356339
  49. Visfatin significantly correlated with BMI and hot flashes number in postmenopausal women with metabolic syndrome. PMID: 27126198
  50. Single nucleotide polymorphism in the NAMPT gene is associated with inflammation in chronic kidney disease. PMID: 27190335

Show More

Hide All

Subcellular Location
Nucleus. Cytoplasm. Secreted.
Protein Families
NAPRTase family
Tissue Specificity
Expressed in large amounts in bone marrow, liver tissue, and muscle. Also present in heart, placenta, lung, and kidney tissues.
Database Links

HGNC: 30092

OMIM: 608764

KEGG: hsa:10135

STRING: 9606.ENSP00000222553

UniGene: Hs.489615

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
webinars: DT3C facilitates antibody internalization X
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*